相关实验视频

Updated: Jul 16, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

低HER2表达对可手术乳腺癌新辅助药疗效的影响

Xiaoli Yi¹, Shasha Hu², Meili Ma¹

¹Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

|September 13, 2023

概括

乳腺癌中HER2的低表达不会显著影响新辅助化疗的疗效或生存结果. 需要进一步的临床数据来确认HER2-low是否代表一个独特的生物亚型.

科学领域:

在瘤学瘤学.
乳腺癌研究研究乳腺癌研究
免疫组织化学免疫组织化学

背景情况:

HER2表达是乳腺癌治疗中的关键生物标志物.
HER2-低和HER2-零表达需要进一步调查治疗反应.
新辅助化疗是可手术的乳腺癌的标准治疗方法.

研究的目的:

为了比较HER2-低和HER2-零乳腺癌患者之间的病理完整反应 (pCR) 率和生存结果.
研究HER2-低与HER2-零乳腺癌的临床特征和治疗疗效.
要确定HER2-低表达是否构成一个独特的生物亚型.

主要方法:

追溯分析86名经过手术的乳腺癌患者.
分类为HER2-零 (IHC分数0) 和HER2-低 (IHC1+或2+/ISH-) 组.
在新辅助化疗后临床特征,pCR率和无病生存期 (DFS) 的比较.

主要成果:

在HER2-低和HER2-零组之间没有观察到pCR率或DFS的显著差异.
低HER2组的复发率和转移率较低 (9.7%与20.8%相比).
在HR+和TNBC患者的亚组分析也显示没有显著的DFS差异.

结论:

在可手术的乳腺癌中,低HER2表达不会显著影响新辅助化疗的疗效.
在HER2-低和HER2-零组之间没有发现临床特征,pCR或DFS的显著差异.
目前的数据不支持HER2-low作为一种独特的生物亚型,因此需要进一步研究.

关键词:

乳腺癌乳腺癌乳腺癌 HER2-低表达的表达方式.新辅助剂是一种新辅助剂.病理完整反应的病理完整反应.

更多相关视频

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...